SCHEMBL21995280

SCHEMBL21995280

Cc1cc(Cl)ccc1S(=O)(=O)CC#N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.43
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CDK7 P50613 1/20 0.37
CCNH P51946 1/20 0.37
CCNA1 P78396 1/20 0.37
TRPV4 Q9HBA0 1/20 0.37
KCNH2 Q12809 2/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
IDH1 O75874 3/20 0.35
PKM P14618 1/20 0.34
TRIM24 O15164 1/20 0.34
BRD1 O95696 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31514033 1.00 GAA (0.43) GAAMAPTMEN1KMT2ACDK1
SCHEMBL21995249 0.83 MEP1B (0.42) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL30773057 0.83 MEP1B (0.42) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL17730411 0.83 FNTA (0.41) MAPTMEN1KMT2ATRPV4ALDH1A1
SCHEMBL18620011 0.80 GAA (0.49) GAAMEN1KMT2ATRPV4
SCHEMBL22056798 0.80 TRPV4 (0.43) MAPTTRPV4TRIM24BRD1BRPF1
SCHEMBL22057010 0.80 CA1 (0.46) KCNH2BRD1BRPF1ALDH1A1FLT1
SCHEMBL17376378 0.80 TSHR (0.44) MEN1KMT2APKMNAMPTALDH1A1
SCHEMBL17376375 0.80 CCR2 (0.43) TRPV4PKMALDH1A1
SCHEMBL3250089 0.79 ALDH1A1 (0.45) GAAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509462-B2 3-(phenylsulfonyl)-[1,2,3]triazolo[1,5A]quinazolin-5(4H)-one derivatives BioVersys AG (CH) 2025-12-30 US disclosed
EP-3887375-B1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2024-11-20 EP disclosed
US-20220024928-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2022-01-27 US disclosed
US-20220024928-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2022-01-27 US disclosed
EP-3887375-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES Bioversys AG (CH) 2021-10-06 EP disclosed
WO-2020109350-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2020-06-04 WO disclosed
WO-2020109350-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024928-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES OR10J3, ORC3, CBR3 GAA 4757/4885MAPT 4658/4885MEN1 2214/4885
US-12509462-B2 3-(phenylsulfonyl)-[1,2,3]triazolo[1,5A]quinazolin-5(4H)-one derivatives CUTA, OR10J3, CCR10 GAA 4842/4885MAPT 2098/4885MEN1 3652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.